Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) CFO Paolantonio Ernest Robert De purchased 1,250 shares of the company’s stock on the open market in a transaction dated Wednesday, June 25th. The stock was purchased at an average cost of $12.13 per share, with a total value of $15,162.50. Following the acquisition, the chief financial officer now directly owns 2,250 shares of the company’s stock, valued at approximately $27,293. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

BioDelivery Sciences International (NASDAQ:BDSI) traded up 1.58% on Monday, hitting $12.20. 207,025 shares of the company’s stock traded hands. BioDelivery Sciences International has a one year low of $4.05 and a one year high of $12.81. The stock’s 50-day moving average is $10.33 and its 200-day moving average is $8.39. The company’s market cap is $591.0 million. BioDelivery Sciences International also was the recipient of unusually large options trading activity on Friday. Investors bought 11,691 call options on the stock. This represents an increase of approximately 463% compared to the average volume of 2,078 call options.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. Analysts expect that BioDelivery Sciences International will post $-0.62 EPS for the current fiscal year.

A number of analysts have recently weighed in on BDSI shares. Analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $18.00 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. Separately, analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $15.50 in a research note on Monday, June 9th. They now have a “buy” rating on the stock. Finally, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday, June 9th. They now have a $15.00 price target on the stock. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $19.25.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.